Schneider; Pascal

Patent Applications and Registrations

Patent applications and USPTO patent grants for Schneider; Pascal.The latest application filed is for "methods of modulating immune responses using bcma polypeptide".

Company Profile

5.23.38

Schneider; Pascal - Pulheim DE
Schneider; Pascal - Epalinges CH
Schneider; Pascal - Lausanne CH
Schneider; Pascal - Espalinges CH

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Sprue system for injection-molding processes Grant 11,059,208 - Alves , et al. July 13, 2	2021-07-13
Methods Of Modulating Immune Responses Using Bcma Polypeptide App 20200095305 - Browning; Jeffrey ; et al.	2020-03-26
Anti APRIL (a proliferation-inducing ligand) antibodies and their uses for the prognosis and/or diagnosis of cancer Grant 10,526,412 - Huard , et al. J	2020-01-07
Sprue System For Injection-molding Processes App 20190366608 - Alves; Bruno ; et al.	2019-12-05
Methods of modulating immune responses using BCMA polypeptide Grant 10,494,416 - Browning , et al. De	2019-12-03
Treatment of X-linked hypohidrotic ectodermal dysplasia with a fusion EDA1 protein Grant 10,426,819 - Schneider , et al. October 1, 2	2019-10-01
Intra-amniotic administration of EDI200 for the treatment of ectodermal dysplasias Grant 10,300,013 - Schneider , et al.	2019-05-28
Methods Of Modulating Immune Responses Using Bcma Polypeptide App 20180273605 - Browning; Jeffrey ; et al.	2018-09-27
Treatment Of X-linked Hypohidrotic Ectodermal Dysplasia With A Fusion Eda1 Protein App 20180169188 - Schneider; Pascal ; et al.	2018-06-21
Treatment of X-linked hypohidrotic ectodermal dysplasia with a fusion EDA1 protein Grant 9,925,239 - Schneider , et al. March 27, 2	2018-03-27
Anti April (a Proliferation-inducing Ligand) Antibodies And Their Uses For The Prognosis And/or Diagnosis Of Cancer App 20170369582 - HUARD; Bertrand ; et al.	2017-12-28
Anti-ectodysplasin antibodies Grant 9,695,245 - Schneider , et al. July 4, 2	2017-07-04
Methods of treating autoimmune diseases using a B-cell maturation antigen (BCMA) Grant 9,650,430 - Browning , et al. May 16, 2	2017-05-16
Intra-amniotic Administration Of Proteins For The Treatment Of Ectodermal Dysplasias App 20160271055 - SCHNEIDER; Pascal ; et al.	2016-09-22
Compositions And Methods For The Treatment Of Ectodermal Dysplasia App 20160272694 - Huttner; Kenneth M. ; et al.	2016-09-22
Treatment of X-linked hypohidrotic ectodermal dysplasia with a fusion EDA1 protein App 20160184393 - Schneider; Pascal ; et al.	2016-06-30
Anti-ectodysplasin Antibodies App 20160075789 - Schneider; Pascal ; et al.	2016-03-17
Treatment of X-linked hypohidrotic ectodermal dysplasia with ectodysplasin A agonist Grant 9,175,085 - Schneider , et al. November 3, 2	2015-11-03
Taci As An Anti-tumor Agent App 20150218247 - Ambrose; Christine ; et al.	2015-08-06
Baff Receptor (bcma), An Immunoregulatory Agent App 20150139992 - Browning; Jeffrey ; et al.	2015-05-21
Fusion Constructs Containing Active Sections Of Tnf Ligands App 20150098944 - Gaide; Olivier ; et al.	2015-04-09
Compositions And Methods For The Alteration Of Xlhed Phenotypes App 20150017161 - Schneider; Pascal ; et al.	2015-01-15
Bimer Or An Oligomer Of A Dimer, Trimer, Quadromer Or Pentamer Of Recombinant Fusion Proteins App 20150004129 - TSCHOPP; Jurg ; et al.	2015-01-01
Pharmaceutical composition comprising EDA-1 Fusion Protein Grant 8,895,003 - Gaide , et al. November 25, 2	2014-11-25
Methods of screening for a compound that inhibits the interaction between BAFF and BCMA Grant 8,828,669 - Browning , et al. September 9, 2	2014-09-09
Preparation of isolated agonist anti-EDAR monoclonal antibodies Grant 8,741,297 - Schneider , et al. June 3, 2	2014-06-03
Fusion Constructs Containing Active Sections Of Tnf Ligands App 20130295093 - GAIDE; Olivier ; et al.	2013-11-07
Preparation Of Isolated Agonist Anti-edar Monoclonal Antibodies App 20130273046 - Schneider; Pascal ; et al.	2013-10-17
Bimer Or An Oligomer Of A Dimer, Trimer, Quadromer Or Pentamer Of Recombinant Fusion Proteins App 20130202552 - TSCHOPP; Jurg ; et al.	2013-08-08
Treatment of ectodermal dysplasia with EDA1 fusion proteins Grant 8,501,177 - Gaide , et al. August 6, 2	2013-08-06
Preparation of isolated agonist anti-EDAR monoclonal antibodies Grant 8,496,937 - Schneider , et al. July 30, 2	2013-07-30
Taci As An Anti-tumor Agent App 20120189634 - Ambrose; Christine ; et al.	2012-07-26
Preparation Of Isolated Agonist Anti-edar Monoclonal Antibodies App 20120192296 - Schneider; Pascal ; et al.	2012-07-26
Bimer Or An Oligomer Of A Dimer, Trimer, Quadromer Or Pentamer Of Recombinant Fusion Proteins App 20120009211 - TSCHOPP; JURG ; et al.	2012-01-12
Fusion Constructs Containing Active Sections Of Tnf Ligands App 20100254984 - Gaide; Olivier ; et al.	2010-10-07
BAFF, inhibitors thereof and their use in the modulation of B-cell response App 20100233179 - Browning; Jeffrey ; et al.	2010-09-16
Fusion constructs containing active sections on TNF ligands Grant 7,736,657 - Gaide , et al. June 15, 2	2010-06-15
Bimer Or An Oligomer Of A Dimer, Trimer, Quatromer Or Pentamer Of Recombinant Fusion Proteins App 20090053252 - Tschopp; Jurg ; et al.	2009-02-26
Bimer or an oligomer of a dimer, trimer, quadromer or pentamer of recombinant fusion proteins Grant 7,385,032 - Tschopp , et al. June 10, 2	2008-06-10
Methods of treating a tumor that expresses APRIL by administering BCMA Grant 7,276,241 - Schneider , et al. October 2, 2	2007-10-02
Methods of treatment by administering an anti-BCMA antibody Grant 7,083,785 - Browning , et al. August 1, 2	2006-08-01
BAFF, inhibitors thereof and their use in the modulation of B-cell response App 20060079457 - Browning; Jeffrey ; et al.	2006-04-13
Hexamers of receptors, members of the tnf receptor family, their use in therapy and pharmaceutical compositions comprising the same App 20050255547 - Tschopp, Jurg ; et al.	2005-11-17
BAFF, inhibitors thereof and their use in the modulation of B-cell response App 20050169924 - Browning, Jeffrey ; et al.	2005-08-04
Fusion constructs cotaining active sections of tnf ligands App 20050152872 - Gaide, Olivier ; et al.	2005-07-14
BAFF, inhibitors thereof and their use in the modulation of B-cell response App 20050100548 - Browning, Jeffrey ; et al.	2005-05-12
BAFF, inhibitors thereof and their use in the modulation of B-cell response Grant 6,869,605 - Browning , et al. March 22, 2	2005-03-22
Bimer or an oligomer of a dimer, trimer, quadromer or pentamer of recombinant fusion proteins App 20040235117 - Tschopp, Jurg ; et al.	2004-11-25
Recombinant fusion proteins and the trimers thereof App 20040197876 - Tschopp, Jurg ; et al.	2004-10-07
Taci as an anti-tumor agent App 20040013674 - Ambrose, Christine ; et al.	2004-01-22
April receptor (BCMA) and uses thereof App 20030082175 - Schneider, Pascal ; et al.	2003-05-01
Bimer or an oligomer of a dimer, trimer, quadromer or pentamer of recombinant fusion proteins App 20030053984 - Tschopp, Jurg ; et al.	2003-03-20
BAFF receptor (BCMA), an immunoregulatory agent App 20020165156 - Browning, Jeffrey ; et al.	2002-11-07
Flip Genes And Flip Proteins App 20020095030 - TSCHOPP, JURG ; et al.	2002-07-18
BAFF, inhibitors thereof and their use in the modulation of B-cell response App 20020037852 - Browning, Jeffrey ; et al.	2002-03-28

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.